BSX vs. BDX, SYK, DXCM, RMD, WST, CI, REGN, VRTX, GILD, and BMY
Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include Becton, Dickinson and Company (BDX), Stryker (SYK), DexCom (DXCM), ResMed (RMD), West Pharmaceutical Services (WST), The Cigna Group (CI), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY). These companies are all part of the "medical" sector.
Becton, Dickinson and Company (NYSE:BDX) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.
Boston Scientific has lower revenue, but higher earnings than Becton, Dickinson and Company. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
In the previous week, Boston Scientific had 37 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 51 mentions for Boston Scientific and 14 mentions for Becton, Dickinson and Company. Boston Scientific's average media sentiment score of 0.89 beat Becton, Dickinson and Company's score of 0.23 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.
86.7% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.3% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.7% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Becton, Dickinson and Company has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Boston Scientific received 394 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 69.04% of users gave Boston Scientific an outperform vote while only 62.25% of users gave Becton, Dickinson and Company an outperform vote.
Becton, Dickinson and Company currently has a consensus target price of $279.17, indicating a potential upside of 17.44%. Boston Scientific has a consensus target price of $66.62, indicating a potential downside of 0.92%. Given Boston Scientific's higher probable upside, equities analysts plainly believe Becton, Dickinson and Company is more favorable than Boston Scientific.
Boston Scientific has a net margin of 11.19% compared to Boston Scientific's net margin of 6.44%. Becton, Dickinson and Company's return on equity of 15.99% beat Boston Scientific's return on equity.
Summary
Boston Scientific beats Becton, Dickinson and Company on 15 of the 19 factors compared between the two stocks.
Get Boston Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Boston Scientific Competitors List
Related Companies and Tools